These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12440275)

  • 41. The role of high density lipoprotein in Type 1 Gaucher disease.
    Watad S; Abu-Saleh N; Yousif A; Agbaria A; Rosenbaum H
    Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase.
    Young E; Chatterton C; Vellodi A; Winchester B
    J Inherit Metab Dis; 1997 Aug; 20(4):595-602. PubMed ID: 9266398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.
    Rosenthal DI; Doppelt SH; Mankin HJ; Dambrosia JM; Xavier RJ; McKusick KA; Rosen BR; Baker J; Niklason LT; Hill SC
    Pediatrics; 1995 Oct; 96(4 Pt 1):629-37. PubMed ID: 7567322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease.
    Campbell PE; Harris CM; Vellodi A
    Neurology; 2004 Jul; 63(2):385-7. PubMed ID: 15277647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ultrastructural features of gaucher disease treated with enzyme replacement therapy presenting as mesenteric mass lesions.
    Fowler DJ; Weber MA; Anderson G; Malone M; Sebire NJ; Vellodi A
    Fetal Pediatr Pathol; 2006; 25(5):241-8. PubMed ID: 17438664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Home treatment with enzyme replacement therapy in a 5-year-old girl with type 2 Gaucher disease.
    Migita M; Shimada T; Hayakawa J; Zhi CL; Morita T; Ohshiro K; Fukunaga Y
    Pediatr Int; 2003 Jun; 45(3):363-5. PubMed ID: 12828600
    [No Abstract]   [Full Text] [Related]  

  • 48. Neurological outcome of a patient with Gaucher disease type III treated by enzymatic replacement therapy.
    Dobbelaere D; Sukno S; Defoort-Dhellemmes S; Lamblin MD; Largillière C
    J Inherit Metab Dis; 1998 Feb; 21(1):74-6. PubMed ID: 9501273
    [No Abstract]   [Full Text] [Related]  

  • 49. [Gaucher's disease with D409H/D409H genotype. evolution with enzyme replacement therapy].
    Castelló Girona F; Domínguez Luengo C; del Toro Riera M; Chabás Bergon A
    An Esp Pediatr; 2001 Mar; 54(3):310-2. PubMed ID: 11262263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metaphyseal undertubulation in gaucher disease: resolution at MRI in a patient undergoing enzyme replacement therapy.
    Kelman CG; Disler DG
    J Comput Assist Tomogr; 2000; 24(1):173-5. PubMed ID: 10667678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
    de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE
    Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519
    [No Abstract]   [Full Text] [Related]  

  • 52. MRI of multiple platyspondyly in Gaucher disease: response to enzyme replacement therapy.
    Hill SC; Parker CC; Brady RO; Barton NW
    J Comput Assist Tomogr; 1993; 17(5):806-9. PubMed ID: 8370839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.
    Migita M; Hamada H; Fujimura J; Watanabe A; Shimada T; Fukunaga Y
    Eur J Pediatr; 2003 Jul; 162(7-8):524-525. PubMed ID: 12845529
    [No Abstract]   [Full Text] [Related]  

  • 55. [Gaucher's disease and enzyme replacement therapy].
    Cornu F
    Ann Pharm Fr; 1998; 56(3):102-7. PubMed ID: 9770016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy.
    Magnaldi S; Longo R; Ukmar M; Zanatta M; Bottega M; Sottocasa GL
    Eur Radiol; 1997; 7(4):486-91. PubMed ID: 9204325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correction of neutrophil chemotaxis defect in patients with Gaucher disease by low-dose enzyme replacement therapy.
    Zimran A; Abrahamov A; Aker M; Matzner Y
    Am J Hematol; 1993 May; 43(1):69-71. PubMed ID: 8317468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gaucher disease: unmet treatment needs.
    Mehta A
    Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Enzyme therapy of Gaucher's disease].
    Beck M
    Dtsch Med Wochenschr; 1993 Jun; 118(25):964-5. PubMed ID: 8519225
    [No Abstract]   [Full Text] [Related]  

  • 60. Resolution of a proximal humeral defect in type-1 Gaucher disease by enzyme replacement therapy.
    Pastores GM; Hermann G; Norton K; Desnick RJ
    Pediatr Radiol; 1995; 25(6):486-7. PubMed ID: 7491212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.